Web Site Helps Men Evaluate Risk of Prostate Cancer

Evergreen Park, IL (PRWEB) September 18, 2006 –

In 2006, more than 234,000 American men will be diagnosed with prostate cancer, and more than 27,000 men will die from the disease, according to the American Cancer Society. while it is estimated that 1 man in 6 will suffer from prostate cancer in his lifetime, only 1 man in 34 will die from it. the earlier the disease is diagnosed and treated, the more likely it is for patients to survive and remain disease-free.

A new Web site published by Little Company of Mary Hospital and Health Care Centers in the Southwest Chicago area (PursuingPainFreeCancer.org) encourages men to learn more about prostate cancer, and to take a free confidential on-line risk test to evaluate their prostate cancer risk. the Web site’s prostate cancer risk test evaluates a man’s risk based on certain genetic and lifestyle factors that scientists believe affect one’s prostate cancer risk.

Knowing one’s risk can significantly increase a man’s chance for surviving prostate cancer. According to Dr. Paul Y. Song, a prostate cancer specialist at Little Company of Mary, “Knowing your risk and early detection provide the best tools to fight prostate cancer. if the disease is diagnosed early, a patient has an excellent prognosis, many treatment options, and typically suffers from fewer side effects.” When the disease is still confined to the prostate, the five-year relative survival rate is nearly 100 percent. “Men whose cancer is diagnosed early may be candidates for any of the accepted prostate cancer treatments,” Dr. Song said.

Some of the treatment options include radiation therapy and surgery. “During the last 20 years, major clinical evidence has shown that both surgery and radiation therapy offer an equal chance for cure in the treatment of prostate cancer,” Dr. Song notes.

Little Company of Mary Hospital is the only hospital in the entire greater Chicago area to offer both High Dose Rate (HDR) brachytherapy for prostate cancer treatment and the da Vinci robotic prostatectomy.

High dose rate brachytherapy provides the most precise delivery of radiation possible in the treatment of prostate cancer. unlike permanent seed implants, patients have temporary placement of radioactive catheters which can be custom tailored to deliver precision internal radiation and better avoid the urethra, rectum, and nerves to reduce overall toxicity without being radioactive and exposing family members to radiation. it is a one-day procedure where patients can go back to work the very next day. “HDR brachytherapy takes the prostate implant procedure to a whole new level, and is more precise and less toxic than conventional seed implants,“ Dr. Song said.

The da Vinci robotic surgical system is a state-of-the-art minimally-invasive technology which allows surgeons to perform complex surgeries through tiny openings. Patients who undergo daVinci prostatectomies typically enjoy fewer overall side effects, shorter hospital stays, and earlier returns to full activities.

At its earliest stages, prostate cancer does not present with any symptoms. Therefore knowing one’s risk and early detection for prostate cancer are a man’s best defenses. “Once cancer cells are found outside the prostate, a man has much fewer treatment options and less potential for cure,” Dr. Song said. Little Company of Mary’s on-line prostate cancer risk test at PursuingPainFreeCancer.org “is a great tool to become more knowledgeable about prostate cancer.”

For more information contact:

Attachments

, Vocus PRW Holdings, LLC. Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Related Prostate Pain Symptoms Press Releases

DOCTORS at Austin Health have developed a genetic test that can predict how people with hepatitis C are likely to respond to treatment.

Gastroenterologist Dr Paul Froomes said hep C patients underwent 48 weeks of treatment, combining the drugs pegylated interferon and ribavirin.

The treatment has been associated with a number of side-effects, including flu-like symptoms such as fever, chills, muscle aches and headaches.

Dr Froomes said he approached microbiologist Dr Volker Gurtler to devise the genetic test nine months ago after breakthrough studies in Switzerland and the US found hep C patients who had the polymorphic gene rs12979860 responded significantly better to the drugs.

“If you’re positive for this genetic test, then your chance of eradicating hep C with current treatment goes up to about 80 per cent,” Dr Froomes said.

“If you tested negative for this polymorphism, then your chance of responding to treatment falls to 30 per cent.” He said patients who found they had a lower success rate to treatment could consider trying alternative new treatments.

He said new treatments for hep C were “just around the corner”.

Hep C causes liver inflammation and liver disease, and is spread through blood-to-blood contact.

In may, the Heidelberg Leader reported an increase in hep C presentations at the Austin Hospital, including a number of patients infected through intravenous drug use. Dr Froomes said the hospital treated about 400 patients with the virus a year.